Renerva
Pittsburgh, US · Founded 2017 · Delaware LLC
Renerva develops surgical products aimed at improving nerve healing and recovery following nerve injury. The company operates in the medical device and biotechnology space focused on nerve repair solutions.
BiotechHealthtechMedical Devices
Founders & leadership
LS
Lorenzo SolettiLLC Manager
BN
Bryan N. BrownChief Technology Officer
WA
William A SekkelLLC Manager
PD
Peter DeComoLLC Manager
JC
J. Christopher FlahertyExecutive Vice President for Intellectual Property
PA
Paul A GardnerChief Medical Officer
JC
Jonathan CheethamChairman of the Scientific Advisory Board
Competitors · 8
by search overlapMinerva Biotechnologies14 shared keywordsMinerva Biotechnologies develops cancer and stem cell therapeutics, including cancer immunotherapies aimed at solid tumors and preventing cancer metastasis. The company also works on patient-derived stem cells for regenerative medicine.
Minerva Neurosciences14 shared keywordsMinerva Neurosciences is a biopharmaceutical company developing therapies for central nervous system disorders, including schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. It focuses on treatments for areas of high unmet medical need.
Diabetes Prevention Program9 shared keywords
Cowles_Investments_StemCentrx8 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Massdevice7 shared keywordsMassDevice is a news and media outlet covering the medical device industry, publishing articles, special reports, and white papers on medtech companies, products, and regulatory topics such as FDA 510(k) submissions. It serves medical device professionals with industry news and analysis.
LeadIQ7 shared keywords
Fda7 shared keywords
Minerva7 shared keywords
Companies competing with Renerva for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$324.8KraisedSep 2025 · 35 investors · Other Health CareRule 506(b)
▶$324.8KraisedSep 2025 · 35 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter DeComoDirector
- Bryan N. BrownExecutive Officer
- William A SekkelDirector
- Lorenzo SolettiExecutive Officer, Director, Promoter
- Offering amount
- $1.5M
- Amount sold
- $324.8K
- Proceeds to insiders
- $53K
- First sale
- Sep 2025
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$335KraisedAug 2024 · 14 investors · Other Health CareRule 506(b)
▶$335KraisedAug 2024 · 14 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lorenzo SolettiExecutive Officer, Director
- Bryan N. BrownExecutive Officer
- William A SekkelDirector
- Peter DeComoDirector
- Offering amount
- $1.5M
- Amount sold
- $335K
- Proceeds to insiders
- $75K
- First sale
- Jul 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$617.3KraisedAug 2018 · 12 investors · Other Health CareRule 506(b)
▶$617.3KraisedAug 2018 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- J. Christopher FlahertyExecutive Officer
- Bryan N. BrownExecutive Officer
- Lorenzo SolettiExecutive Officer, Director
- Paul A GardnerExecutive Officer
- Jonathan CheethamExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $617.3K
- Minimum investment
- $25K
- Proceeds to insiders
- $200K
- First sale
- Jun 2018
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $495K |
| National Science Foundation | Phase II | 2022 | $996.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $274.3K |
| National Science Foundation | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.